Relay Therapeutics, Inc. RLAY
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -88.33% | -57.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -88.33% | -57.14% | |||
| Cost of Revenue | 8.39% | 30.59% | |||
| Gross Profit | -12.68% | -43.64% | |||
| SG&A Expenses | 33.23% | -18.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.75% | 20.64% | |||
| Operating Income | -15.57% | -29.62% | |||
| Income Before Tax | -14.21% | -33.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.21% | -33.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.21% | -33.52% | |||
| EBIT | -15.57% | -29.62% | |||
| EBITDA | -15.85% | -30.08% | |||
| EPS Basic | -1.28% | -28.75% | |||
| Normalized Basic EPS | -1.26% | -28.77% | |||
| EPS Diluted | -1.28% | -28.75% | |||
| Normalized Diluted EPS | -1.26% | -28.77% | |||
| Average Basic Shares Outstanding | 12.79% | 3.72% | |||
| Average Diluted Shares Outstanding | 12.79% | 3.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||